Group 1 - The company approved an investment in a joint venture, PharmaGend Global Medical Services Pte. Ltd., located in Singapore, with partners CMS Medical Venture Pte. Ltd., Rxilient Health Pte. Ltd., and Healthy Goal Limited [1][4] - The joint venture aims to raise $30 million through the issuance of 30 million Class A preferred shares, primarily for infrastructure and operational expenses [3][8] - The company plans to invest $10.5 million, corresponding to its 35% ownership in the joint venture, as part of the additional investment [2][8] Group 2 - The ownership structure of the joint venture post-investment will be as follows: the company will hold 32.38%, CMS Medical Venture will hold 31.27%, Rxilient Health will hold 10.36%, and Healthy Goal Limited will hold 18.50% [3][7] - The joint venture's financial data indicates total assets of $98.48 million and total liabilities of $40.32 million as of the latest reporting period [7][8] - The investment is expected to enhance the joint venture's capabilities in the Southeast Asian CDMO service market, contributing to the company's global and sustainable development [10][12] Group 3 - The investment transaction is classified as a related party transaction, with necessary approvals obtained from the board, excluding related directors from voting [4][10] - The company emphasizes that the additional investment will not alter its control over the joint venture or significantly impact its financial results [10][12] - The independent directors have reviewed the transaction and concluded that it will not harm the interests of the company or its shareholders, particularly minority shareholders [12]

上海妙道企业管理咨询有限公司 关于 康龙化成（北京）新药技术股份有限公司 第四个归属期归属条件成就相关事项 之 独立财务顾问报告 独立财务顾问： 二〇二五年八月 上海妙道企业管理咨询有限公司 独立财务顾问报告 一、董事会就本次激励计划设定的限制性股票归属条件是否成就的审议情况 .....10 二、本次归属条件成就之日和第四个归属期限制性股票继续禁售的说明 .........13 上海妙道企业管理咨询有限公司 独立财务顾问报告 第一章 声 明 上海妙道企业管理咨询有限公司接受委托，担任康龙化成（北京）新药技 术股份有限公司（以下简称"康龙化成""上市公司"或"公司"）2021 年 A 股限制性股票激励计划（以下简称"本激励计划"）的独立财务顾问（以下简 称"本独立财务顾问"），并制作本独立财务顾问报告。本独立财务顾问报告 是根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司股权 激励管理办法》《深圳证券交易所创业板上市公司自律监管指南第 1 号——业 务办理》等法律、法规和规范性文件的有关规定，在康龙化成提供有关资料的 基础上，发表独立财务顾问意见，以供康龙化成全体股东及有关各方参考。 一、本独立财 ...

上海妙道企业管理咨询有限公司 关于 康龙化成（北京）新药技术股份有限公司 第三个归属期归属条件成就相关事项 之 独立财务顾问报告 独立财务顾问： 二〇二五年八月 上海妙道企业管理咨询有限公司 独立财务顾问报告 目 录 一、董事会就本次激励计划设定的限制性股票归属条件是否成就的审议情况 .....10 二、本次归属条件成就之日和第三个归属期限制性股票继续禁售的说明 .........13 上海妙道企业管理咨询有限公司 独立财务顾问报告 第一章 声 明 上海妙道企业管理咨询有限公司接受委托，担任康龙化成（北京）新药技 术股份有限公司（以下简称"康龙化成""上市公司"或"公司"）2022 年 A 股限制性股票激励计划（以下简称"本激励计划"）的独立财务顾问（以下简 称"本独立财务顾问"），并制作本独立财务顾问报告。本独立财务顾问报告 是根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司股权 激励管理办法》《深圳证券交易所创业板上市公司自律监管指南第 1 号——业 务办理》等法律、法规和规范性文件的有关规定，在康龙化成提供有关资料的 基础上，发表独立财务顾问意见，以供康龙化成全体股东及有关各方参考。 一、 ...

北京市中伦律师事务所 关于康龙化成（北京）新药技术股份有限公司 个归属期归属条件成就但股票暂不上市 及部分限制性股票作废事项的 法律意见书 二〇二五年八月 北京 • 上海 • 深圳 • 广州 • 武汉 • 成都 • 重庆 • 青岛 • 杭 州 • 南京 • 海口 • 东京 • 香港 • 伦敦 • 纽约 • 洛杉矶 • 旧金山 • 阿拉木图 Beijing • Shanghai • Shenzhen • Guangzhou • Wuhan • Chengdu • Chongqing • Qingdao • Hangzhou • Nanjing • Haikou • Tokyo • Hong Kong • London • New York • Los Angeles • San Francisco • Almaty 法律意见书 目 录 北京市中伦律师事务所 关于康龙化成（北京）新药技术股份有限公司 第四个归属期归属条件成就但股票暂不上市 及部分限制性股票作废事项的 法律意见书 致：康龙化成（北京）新药技术股份有限公司 根据康龙化成（北京）新药技术股份有限公司（以下简称"康龙化成"、 "公 司"）与北京市中伦律师 ...

北京市中伦律师事务所 关于康龙化成（北京）新药技术股份有限公司 及部分限制性股票作废事项的 根据《公司法》《证券法》《上市公司股权激励管理办法》（以下简称《管理 办法》）等法律、法规、规范性文件和《康龙化成（北京）新药技术股份有限公 司章程》 （以下简称《公司章程》 ）等有关规定，就公司本次股权激励计划授予价 | 法律意见书 | | | | 二〇二五年八月 | | --- | --- | --- | --- | --- | | 北京 • 上海 • 深圳 • 广州 • 武汉 • 成都 • 重庆 • 青岛 • 杭 | | | | | | 州 • 南京 • 海口 • 东京 • 香港 • 伦敦 • • 洛杉矶 • | | | 纽约 | | | 旧金山 • 阿拉木图 | | | | | | Beijing • Shanghai • Shenzhen • Wuhan • Chengdu • Chongqing • Qingdao • Hangzhou • Nanjing | Guangzhou | • | | | | • Haikou • Tokyo • Hong Kong • London • New York • L ...

Core Viewpoint - The legal opinion from Zhonglun Law Firm addresses the conditions for the third vesting period of the restricted stock incentive plan of Kanglong Chemical (Beijing) New Drug Technology Co., Ltd., indicating that the conditions have been met but the stocks will not be listed for trading at this time [1][12]. Summary by Sections Legal Opinion Overview - The legal opinion is based on the review of the 2022 A-share restricted stock incentive plan and related documents, confirming compliance with relevant laws and regulations [4][7]. Approval and Authorization - The adjustments, vesting, and cancellation of certain restricted stocks have been approved by the company's board and independent directors, ensuring compliance with the management regulations [6][8]. Vesting Conditions - The third vesting period for the restricted stocks is defined as starting from the first trading day after 36 months from the grant date, which was July 28, 2022, and will last until the last trading day within 48 months [8][11]. - The conditions for vesting have been met, including no adverse audit opinions and the fulfillment of performance targets [9][10]. Performance Metrics - The company’s revenue for 2024 is projected to be approximately 12.28 billion, representing a growth of at least 60% compared to 2021's revenue of about 7.44 billion [9][10]. Cancellation of Restricted Stocks - A total of 44,104 shares of restricted stock granted to 10 individuals who left the company have been declared void, in accordance with the incentive plan [11][12]. Conclusion - The legal opinion concludes that all necessary approvals have been obtained, the third vesting period conditions have been satisfied, and the actions taken are in compliance with applicable laws and regulations [12].

Core Viewpoint - The company has achieved the vesting conditions for the third vesting period of its 2022 A-share restricted stock incentive plan, but the stocks will not be listed until January 27, 2026, due to a commitment from all incentive recipients to not transfer their vested stocks within six months of the vesting condition achievement [1][22][24]. Summary by Sections Incentive Plan Overview - The incentive plan involves granting 1,548,800 restricted stocks, accounting for 0.20% of the company's total share capital of 794,177,098 shares [2][3]. - The grant price for the restricted stocks is set at 58.38 CNY per share [2]. Vesting Conditions - The vesting conditions for the third period require a revenue growth rate of at least 60% in 2024 compared to 2021, which was achieved with a revenue of approximately 12.28 billion CNY, reflecting a 64.91% increase [16][18]. - A total of 336 incentive recipients met the vesting conditions, with 681,766 shares eligible for vesting, representing 0.04% of the total share capital at the time of the board's decision [22][24]. Performance Assessment - The performance assessment for individual recipients is based on internal evaluation, with a binary outcome of "qualified" or "not qualified," determining the vesting ratio of the restricted stocks [18][19]. - The company has confirmed that all 336 recipients met the necessary performance criteria for the vesting of their stocks [24]. Future Actions - The company will apply for the vesting procedures with the Shenzhen Stock Exchange and the China Securities Depository and Clearing Corporation after the end of the lock-up period [1][22]. - The company will continue to monitor the impact of the stock vesting on its financial status and operational results, ensuring compliance with relevant regulations [23][24].

Core Viewpoint - The company announced adjustments to the grant prices of its A-share restricted stock incentive plans for 2021, 2022, and 2023 due to the implementation of the 2024 annual equity distribution plan [1][2]. Summary by Sections Adjustments to Incentive Plans - The grant price for the 2021 A-share incentive plan has been adjusted from 30.59 yuan/share to 30.39 yuan/share - The grant price for the 2022 A-share incentive plan has been adjusted from 25.35 yuan/share to 25.15 yuan/share - The grant price for the 2023 A-share incentive plan has been adjusted from 18.65 yuan/share to 18.45 yuan/share [2] Impact on the Company - The adjustments to the grant prices of the incentive plans will not have a substantial impact on the company's financial status and operating results [3]. Supervisory Board Opinion - The supervisory board believes that the adjustments comply with relevant laws and regulations and do not harm the interests of the company and all shareholders [4]. Legal Opinion - The legal opinion confirms that the necessary authorizations and approvals for the adjustments have been obtained and that the adjustments comply with relevant regulations [4].

Core Viewpoint - The company announced the cancellation of unvested restricted stock from its 2021, 2022, and 2023 A-share incentive plans due to the departure of certain incentive recipients and unmet performance targets [1][2]. Summary by Sections 1. Cancellation of Restricted Stocks - The company decided to cancel a total of 634,880 shares from the 2021, 2022, and 2023 A-share incentive plans due to the following reasons: - 42,189 shares from the 2021 plan due to one recipient's departure [2] - 44,104 shares from the 2022 plan due to ten recipients' departures [2] - 634,880 shares from the 2023 plan, which includes: - 179,553 shares due to ten recipients' departures - 455,327 shares due to unmet performance targets for the second vesting period [2][4] 2. Impact on the Company - The cancellation of these restricted stocks is not expected to have a material impact on the company's financial condition or operational results [2] - The stability of the core team is also not anticipated to be affected, and the incentive plans will continue to be implemented as planned [2] 3. Supervisory Board Opinion - The supervisory board reviewed the situation and agreed with the cancellation based on the reasons provided, confirming that the actions comply with relevant laws and regulations [3][4] 4. Legal Opinion - A legal opinion confirmed that the necessary authorizations and approvals for the cancellation have been obtained, and the actions are in accordance with applicable laws and the incentive plans [4]

Core Viewpoint - Kanglong Chemical reported a mixed performance in its semi-annual earnings, with revenue growth but a significant decline in net profit and earnings per share [2] Financial Performance - The company achieved approximately 6.441 billion yuan in revenue for the first half of 2025, representing a year-on-year increase of 14.93% [2] - The net profit attributable to shareholders was around 701 million yuan, showing a year-on-year decrease of 37% [2] - Basic earnings per share were 0.3984 yuan, down 36.58% compared to the previous year [2]